Insiders who reported open-market trades in the last 12 months at the companies Paul B. Manning files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Paul Peter Tak - $3.16M in CADL purchases and sales in the last 12 months
Francesca Barone - $236K in CADL purchases and sales in the last 12 months
Seshu Tyagarajan - $154K in CADL purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Paul B. Manning is a corporate insider, tracked as Director of Candel Therapeutics, Inc. (CADL). InsiderAlpha holds 12 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Paul B. Manning submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Paul B. Manning been buying or selling stock?
Recorded transactions: 13 open-market purchases ($28.01M) and 9 open-market sales ($31.74M) across all tracked filings.
Paul B. Manning is Director of Candel Therapeutics, Inc. (CADL). 12 SEC Form 4 filings on record going back to 2024, most recently on 2 October 2026. Most recent open-market trade: sold $812K of LQDA on 8 June 2026. Lifetime open-market purchases: $28.01M. Lifetime open-market sales: $31.74M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Paul B. Manning.
InsiderAlpha's records for Paul B. Manning go back to 2024: 12 primary Form 4 filings, an average of 4.0 per year. The typical open-market purchase is $5.60M (5 of 13 buys carry a usable dollar value, totaling $28.01M). The largest single buy on record is $11.67M of VRCA in 2025. Sales side: 9 recorded sales totaling $31.74M, so the filing history runs sell-heavy by dollar value. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
